Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling-Reference-Cited by-同舟云学术

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling

Published:2021-10-12 Issue: Volume: Page:
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Montanha Maiara Camotti,Fabrega Francesc,Howarth Alice,Cottura Nicolas,Kinvig Hannah,Bunglawala Fazila,Lloyd Andrew,Denti Paolo,Waitt Catriona,Siccardi Marco

Funder

European and Developing Countries Clinical Trials Partnership

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-021-01067-1.pdf

Reference75 articles.

1. World Health Organization. Tuberculosis and HIV. https://www.who.int/hiv/topics/tb/about_tb/en/.

2. Global tuberculosis report 2019. https://www.who.int/tb/publications/global_report/en/.

3. Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13:22. https://doi.org/10.1186/s12981-016-0106-y.

4. Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23(2): e25449. https://doi.org/10.1002/jia2.25449.

5. Marzolini C, Battegay M, Back D. Mechanisms of drug interactions II: transport proteins. Drug interactions in infectious diseases. Totowa: Humana Press; 2011. https://doi.org/10.1007/978-3-319-72422-5_3.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically‐based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co‐administered with ritonavir;CPT: Pharmacometrics & Systems Pharmacology;2024-06-20

2. Attaining Equity of Access to Research: Perspective on Research in Pregnancy and Breastfeeding Following Dolores Shockley Lecture at ASCPT2024;Clinical Pharmacology & Therapeutics;2024-06-12

3. In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells;Scientific Reports;2024-05-10

4. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes;Clinical Pharmacology & Therapeutics;2024-03

5. Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy;British Journal of Clinical Pharmacology;2024-02-10